These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 541407)

  • 21. Improved liquid chromatographic assay for the analysis of pirmenol in plasma and urine.
    Johnson EL; Pachla LA
    J Pharm Sci; 1984 Jun; 73(6):754-6. PubMed ID: 6737258
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-performance liquid chromatographic method for the quantitation of a meta-O-dealkylated metabolite of flecainide acetate, a new antiarrhythmic.
    Chang SF; Welscher TM; Miller AM; McQuinn RL; Fox JM
    J Chromatogr; 1985 Sep; 343(1):119-27. PubMed ID: 4066846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chromatographic (TLC) analysis of diltiazem in pharmaceutical form in presence of other antiarrhythmics.
    Witek A; Przyborowski L
    Acta Pol Pharm; 1996; 53(1):9-12. PubMed ID: 8960279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-performance liquid chromatographic method for the quantitation of flecainide, a new antiarrhythmic, in human plasma and urine.
    Chang SF; Welscher TM; Miller AM; Ober RE
    J Chromatogr; 1983 Feb; 272(2):341-50. PubMed ID: 6833431
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison in vitro of the electrophysiological effects of lorcainide and its metabolite norlorcainide.
    Carmeliet E
    Eur J Pharmacol; 1987 Jan; 133(1):29-36. PubMed ID: 3556390
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapid and simple method for determination of lorcainide, a new antiarrhythmic drug, and its major metabolite, norlorcainide, by high-performance liquid chromatography.
    Simon V; Somani P
    J Chromatogr; 1982 Sep; 231(2):478-84. PubMed ID: 7130327
    [No Abstract]   [Full Text] [Related]  

  • 27. Liquid-chromatographic determination of propisomide and its mono-N-dealkylated metabolite in plasma and urine.
    Houin G; Jeanniot JP; Ledudal P; Barré J; Tillement JP
    Clin Chem; 1985 Jul; 31(7):1222-4. PubMed ID: 4006195
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lorcainide (R 15 889), a first review.
    Amery WK; Heykants JJ; Xhonneux R; Towse G; Oettel P; Gough DA; Janssen PA
    Acta Cardiol; 1981; 36(3):207-34. PubMed ID: 7020313
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical importance of metabolites of antiarrhythmic drugs.
    Kates RE; Woosley RL; Harrison DC
    Am J Cardiol; 1984 Jan; 53(1):248-51. PubMed ID: 6419577
    [No Abstract]   [Full Text] [Related]  

  • 30. Lorcainide disposition kinetics in arrhythmia patients.
    Kates RE; Keefe DL; Winkle RA
    Clin Pharmacol Ther; 1983 Jan; 33(1):28-34. PubMed ID: 6848296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prehepatic and hepatic first-pass metabolism of lorcainide in rats.
    Plänitz V; Grönniger J; Jähnchen E
    Arzneimittelforschung; 1985; 35(6):923-6. PubMed ID: 4026917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gas chromatographic-mass fragmentographic determination of propiverine and its metabolites in plasma and urine.
    Marunaka T; Umeno Y; Minami Y; Matsushima E; Maniwa M; Yoshida K; Nagamachi M
    J Chromatogr; 1987 Sep; 420(1):43-52. PubMed ID: 3667829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistant ventricular arrhythmias treated with lorcainide, a new antiarrhythmic drug.
    Somani P; di Giorgi S
    Chest; 1980 Oct; 78(4):658-60. PubMed ID: 7418495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioavailability and saturation of the presystemic metabolism of oral lorcainide therapy initiated in three different dose regimens.
    Amery WK; Heykants J; Bruyneel K; Terryn R
    Eur J Clin Pharmacol; 1983; 24(4):517-9. PubMed ID: 6861866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Haemodynamic reactions after intravenous injection of lorcainide hydrochloride in acute myocardial infarction.
    Shita A; Bernard R; Mostinckx R; Debacker M
    Eur J Cardiol; 1981; 12(5):237-42. PubMed ID: 7250167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Simultaneous plasma levels determination of mexiletine and one of its metabolites by electron capture gas-liquid chromatography.
    Pachecus A; Santoni Y; Fornaris M; Magnan S; Aubert C; Ragon A; Cano JP
    Arzneimittelforschung; 1982; 32(6):688-93. PubMed ID: 6889428
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effects of lorcainide, a new antiarrhythmic agent, on experimental cardiac arrhythmias].
    Fukuda H; Goto M; Kondo M; Uchigasaki T; Sekino Y
    Nihon Yakurigaku Zasshi; 1983 Feb; 81(2):115-26. PubMed ID: 6852683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Column-switching high-performance liquid chromatography combined with ionspray tandem mass spectrometry for the simultaneous determination of the platelet inhibitor Ro 44-3888 and its pro-drug and precursor metabolite in plasma.
    Zell M; Husser C; Hopfgartner G
    J Mass Spectrom; 1997 Jan; 32(1):23-32. PubMed ID: 9008866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simultaneous assay of triazolam and its main hydroxy metabolite in plasma and urine by capillary gas chromatography.
    Coassolo P; Aubert C; Cano JP
    J Chromatogr; 1983 May; 274():161-70. PubMed ID: 6135700
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hyponatremia in patients treated with lorcainide, a new antiarrhythmic drug.
    Somani P; Temesy-Armos PN; Leighton RF; Goodenday LS; Fraker TD
    Am Heart J; 1984 Dec; 108(6):1443-8. PubMed ID: 6507240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.